The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Exenatide
Metformin
Obesity
Polycystic ovary syndrome
Reproductive function
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
01
12
2022
accepted:
19
03
2023
medline:
21
7
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects women of childbearing age, resulting in reproductive dysfunction, hyperinsulinemia, and obesity. While several drugs are currently approved for use in these patients, their relative effectiveness remains controversial. The purpose of this meta-analysis was to evaluate the reproductive efficacy and safety of exenatide, a glucagon-like peptide-1 receptor agonist, versus metformin, an insulin sensitizer, in the treatment of patients with PCOS. Nine randomized controlled trials (RCTs) were included, comprising 785 PCOS patients, of whom 385 received exenatide and 400 received metformin. Compared with metformin, exenatide was significantly more effective in treating these patients, as demonstrated by increased pregnancy rate (relative risk (RR) = 1.93, 95% confidence interval (CI) 1.28 to 2.92, P = 0.002), greater ovulation rate (RR = 1.41, 95% CI 1.11 to 1.80, P = 0.004), decreased body mass index (mean difference = - 1.72 kg/m
Identifiants
pubmed: 37002532
doi: 10.1007/s43032-023-01222-y
pii: 10.1007/s43032-023-01222-y
pmc: PMC10354168
doi:
Substances chimiques
Metformin
9100L32L2N
Exenatide
9P1872D4OL
Hypoglycemic Agents
0
Types de publication
Meta-Analysis
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2349-2361Informations de copyright
© 2023. The Author(s).
Références
Clin Chim Acta. 2020 Mar;502:214-221
pubmed: 31733195
Clin Endocrinol (Oxf). 2017 Dec;87(6):767-774
pubmed: 28834553
Hum Reprod. 1995 Aug;10(8):2107-11
pubmed: 8567849
Reprod Health. 2021 Aug 18;18(1):171
pubmed: 34407851
Curr Pharm Des. 2016;22(36):5526-5534
pubmed: 27510482
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9
pubmed: 15181052
Endocr Rev. 2012 Dec;33(6):981-1030
pubmed: 23065822
J Clin Endocrinol Metab. 2008 Jan;93(1):162-8
pubmed: 17925334
Fertil Steril. 2010 Nov;94(6):2385-8
pubmed: 20356587
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32442310
Ann Endocrinol (Paris). 2010 Feb;71(1):25-7
pubmed: 20079483
Postgrad Med. 2015;127(8):818-26
pubmed: 26371721
Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:38-62
pubmed: 35149444
J Clin Endocrinol Metab. 2008 Jul;93(7):2670-8
pubmed: 18460557
Mol Endocrinol. 2005 Feb;19(2):379-90
pubmed: 15514033
Neurochem Int. 2019 Sep;128:94-105
pubmed: 31002893
Horm Res Paediatr. 2017;88(6):371-395
pubmed: 29156452
Nature. 2001 Dec 13;414(6865):799-806
pubmed: 11742412
Expert Rev Clin Pharmacol. 2021 Sep;14(9):1081-1089
pubmed: 34015974
J Am Pharm Assoc (2003). 2012 Jul-Aug;52(4):466-71
pubmed: 22825226
J Ovarian Res. 2019 Sep 16;12(1):86
pubmed: 31526389
Hum Reprod. 2010 Feb;25(2):450-6
pubmed: 19933236
Diabetologia. 2017 Sep;60(9):1577-1585
pubmed: 28776086
Reprod Sci. 2022 Sep;29(9):2465-2476
pubmed: 34046867
Expert Rev Clin Pharmacol. 2017 Apr;10(4):401-408
pubmed: 28276778
Cardiovasc Ther. 2022 Nov 16;2022:6820377
pubmed: 36474714
Diabetes Obes Metab. 2009 Jun;11(6):544-56
pubmed: 19383034
Eur J Endocrinol. 2014 Oct;171(4):P1-29
pubmed: 24849517
Expert Rev Endocrinol Metab. 2021 Mar;16(2):37-47
pubmed: 33634727
Ther Adv Endocrinol Metab. 2021 Jan 27;12:2042018821989238
pubmed: 33552465
Curr Pharm Biotechnol. 2014;15(1):70-83
pubmed: 24720592
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1071-e1083
pubmed: 33211867
Genet Res Int. 2018 Feb 18;2018:7624932
pubmed: 29670770
Hum Reprod. 2012 Oct;27(10):3067-73
pubmed: 22777527
J Clin Endocrinol Metab. 2012 Jan;97(1):198-207
pubmed: 22013105
Sci Rep. 2017 Jul 13;7(1):5339
pubmed: 28706269
J Clin Endocrinol Metab. 2002 Mar;87(3):1282-90
pubmed: 11889200
Eur J Endocrinol. 2010 Feb;162(2):193-212
pubmed: 19841045
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Endocr Rev. 2016 Oct;37(5):467-520
pubmed: 27459230
Endocrinol Metab Clin North Am. 2014 Mar;43(1):123-47
pubmed: 24582095
J Clin Endocrinol Metab. 2011 Jun;96(6):1827-34
pubmed: 21450988
J Clin Endocrinol Metab. 2019 May 1;104(5):1841-1854
pubmed: 30544235
Mediators Inflamm. 2016;2016:3094642
pubmed: 27110066
Diabetes Obes Metab. 2023 Apr;25(4):975-984
pubmed: 36511825
J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1420-e1432
pubmed: 32995892
Mol Cell Endocrinol. 2010 Mar 25;316(2):172-9
pubmed: 19818376
J Obstet Gynaecol. 2022 May;42(4):574-579
pubmed: 34392796
Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):633-7
pubmed: 19998243
Fertil Steril. 2005 May;83(5):1454-60
pubmed: 15866584
Reprod Sci. 2016 Sep;23(9):1242-9
pubmed: 26917422
Fertil Steril. 2013 Jul;100(1):23-38
pubmed: 23472949